• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Wednesday 12/19/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

biotechnology

  • 1:18 PM

    FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of liquid, gel and solid hemostatic and wound care devices, today announced topline data for its irritation/sensitization patch test study of AC5™ Topical Gel (AC5)1. The study was designed to address a request by the Food and Drug Administration (FDA or “the Agency”). These topline results indicate that AC5 is neither an irritant nor a sensitizer. Additionally, no immunogenic response and no

    Read more
  • 2:09 PM

    FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of liquid, gel and solid hemostatic and wound care devices, announced today that it has completed enrollment for its human skin sensitization study and that applications of the Company’s AC5™ Topical Gel are underway for all subjects. The study is anticipated to conclude during the third quarter. Terrence W. Norchi, MD, President and CEO of Arch, said, “This study is an important component of

    Read more
  • 5:55 PM

    Median survival of top 100 patients is 40.5 months,Median survival of all 331 patients is 23.1 months, Longest survivors have exceeded 7 years BETHESDA, Md., May 29, 2018 /PRNewswire-USNewswire/ — Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research

    Read more
  • 5:51 PM

    BEVERLY, Mass., May 29, 2018 (GLOBE NEWSWIRE) — LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into an agreement with the Stanford University School of Medicine.  The agreement involves using a targeted sequencing technology developed in the laboratory of Dr. Hanlee Ji, a Stanford associate professor of medicine, in combination with LexaGene’s microfluidic instrument.  “LexaGene’s technology was originally designed for pathogen detection across very large markets – I’m

    Read more
  • 2:52 PM

    Proceeds To Fund Commercialization of First Approved Drug and Pivotal Clinical Programs in 2018   NEW YORK, January 30, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO) (“Q BioMed” or the “Company”), a commercial stage biotechnology acceleration development company is pleased to announce pricing of a public offering of an aggregate of 1,711,875 shares of common stock of the Company, together with warrants to purchase up to 1,711,875 shares of common stock of the Company, at a public offering price of $3.20 per share

    Read more
  • 11:18 AM

    LOS ANGELES, January 23, 2018 /PRNewswire/ — GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris: GTBP.PA) today announced that it has entered into definitive agreements for a private placement of convertible notes and warrants for gross proceeds of $7,055,000. The company intends to use the proceeds from the financing to advance its immuno-oncology programs, which are based on the company’s proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms, neurology (CNS) pipeline progress, and for

    Read more
Public Wire Banner